Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US Senate clears PEPFAR bill with HIV treatment thresholds

This article was originally published in Scrip

Executive Summary

The US House is expected this week to approve a Senate bill renewing and expanding the President's Emergency Plan for AIDS Relief (PEPFAR) programme. The measure would require more than half of all HIV/AIDS funding be spent on treatment and open an avenue for the PEPFAR programme to purchase antiretrovirals approved by regulators other than the FDA.

You may also be interested in...



Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos

Generics firm will launch single-tablet regimens of older HIV drugs not otherwise available as combos in US, with discounted pricing.

Mylan Plans To Compete In US HIV Market With Two Fixed-Dose Combos

Generics firm will launch single-tablet regimens of older HIV drugs not otherwise available as combos in US, with discounted pricing.

COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers

First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.

Topics

UsernamePublicRestriction

Register

LL026487

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel